Immune rejection after kidney transplantation
Conditions
Interventions
Control group:Standard-dose extended-release tacrolimus regimen
Loading-dose extended-release tacrolimus group:Loading-dose extended-release tacrolimus regimen
Sponsors
Southern Medical University Southern Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Written informed consent provided voluntarily; 2.Patients undergoing first allogeneic kidney transplantation at Nanfang Hospital, Southern Medical University; 3.Age between 18 and 65 years; 4. CYP3A5 genotype is slow metabolizer.
Exclusion criteria
Exclusion criteria: 1.Concomitant use of medications significantly affecting CYP3A4 metabolism (except corticosteroids), such as voriconazole, ketoconazole, and macrolide antibiotics; 2.History of previous organ transplantation; 3.Use of tacrolimus, cyclosporine, sirolimus, or everolimus within 3 months prior to enrollment; 4.Panel reactive antibody (PRA) > 30%; 5.Any condition judged by investigators to make the patient unsuitable for participation in this study;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tacrolimus whole blood trough concentration (C?); | — |
Secondary
| Measure | Time frame |
|---|---|
| Urinalysis parameters;Renal function parameters;Incidence of delayed graft function (DGF) in transplanted kidneys; | — |
Countries
China
Contacts
Public ContactMiao Yun
Southern Medical University Southern Hospital
Outcome results
None listed